BioMark, a research group of ISEP, is developing biosensors that will allow early diagnosis of Alzheimer's disease. The R&D group is part of 2IQBioneuro, a cooperation project between Portugal and Spain that, until 2022, will develop new solutions for the diagnosis and treatment of neurological diseases that are associated with aging.

This method will identify Alzheimer's in the early stages of the disease, improving patient quality of life: "The analysis of biomarkers allows early diagnosis and the patient is submitted to medication and therapies earlier that may delay the disease", explains Felismina Moreira, researcher and project coordinator at Biomark.

This is a less invasive and low-cost method and can be used by professionals in hospitals and health centers to diagnose the disease, in a simple and quick way.

José Puga and Judite Sousa, professors of the Department of Electrotechnical Engineering at ISEP, are developing a multiple reading connector device to detect, at the same time, three biomarkers associated with Alzheimer's disease.

2IQBioneuro, launched in 2019, is financed by INTERREG 2014-2020 Program. It is led by Universidade de Santiago de Compostela and includes ISEP, Universidade de Vigo, Universidad de Valladolid, Fundación Centro de Cirugía de Mínima Invasión Jesús Usón, Qubiotech Health Intelligence SL, Lincbiotech, SL, Universidade do Minho, Universidade de Coimbra and Fundación Instituto de Investigación Sanitaria de Santiago de Compostela.